FYREMADEL Drug Patent Profile
Which patents cover Fyremadel, and what generic alternatives are available?
Fyremadel is a drug marketed by Sun Pharm and is included in one NDA.
The generic ingredient in FYREMADEL is ganirelix acetate. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the ganirelix acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fyremadel
A generic version of FYREMADEL was approved as ganirelix acetate by ORGANON USA ORGANON on July 29th, 1999.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FYREMADEL?
- What are the global sales for FYREMADEL?
- What is Average Wholesale Price for FYREMADEL?
Summary for FYREMADEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 147 |
| Drug Prices: | Drug price information for FYREMADEL |
| DailyMed Link: | FYREMADEL at DailyMed |
Recent Clinical Trials for FYREMADEL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Andros Day Surgery Clinic | NA |
Pharmacology for FYREMADEL
| Drug Class | Gonadotropin Releasing Hormone Receptor Antagonist |
| Mechanism of Action | Gonadotropin Releasing Hormone Receptor Antagonists |
| Physiological Effect | Decreased GnRH Secretion |
US Patents and Regulatory Information for FYREMADEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | FYREMADEL | ganirelix acetate | INJECTABLE;INJECTION | 204246-001 | Nov 30, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
